

FORM PTO-1390 (REV. 10-2003)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER D0185 PCT	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold;">10/501035</div>	
INTERNATIONAL APPLICATION NO. PCT/US03/01981		INTERNATIONAL FILING DATE January 17, 2003		PRIORITY DATE CLAIMED January 18, 2002	
TITLE OF INVENTION - IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS					
APPLICANT(S) FOR DO/EO/US Fei Huang, Craig R. Fairchild, Francis Y. Lee					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. (Sequence listing is on 3 CD-Roms enclosed herewith) 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information: 					

U.S. APPLICATION NO. (if known, see 37 CFR 1.53)

10/501035

INTERNATIONAL APPLICATION NO.
PCT/US03/01981ATTORNEY'S DOCKET NUMBER
D0185 PCT21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO. \$1080.00International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$920.00International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00**ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS PTO USE ONLY**

\$ 100.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months
from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	40 - 20 =	20	x \$18.00	\$ 360.00
Independent claims	5 - 3 =	2	x \$86.00	\$ 172.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$290.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2.

\$

SUBTOTAL =

\$

Processing fee of \$130.00 for furnishing the English translation later than 30 months
from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =

\$ 632.00

Amount to be
refunded:

\$

charged:

\$

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.b. ☒ Please charge my Deposit Account No. 19-3880 in the amount of \$ 632.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 19-3880. A duplicate copy of this sheet is enclosed.d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card**
information should not be included on this form. Provide credit card information and authorization on PTO-2038.**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a)
or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Stephen C. D'Amico
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000

SIGNATURE

Stephen C. D'Amico

NAME

46,652

REGISTRATION NUMBER

PATENT
Docket No.: D0185 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Fei HUANG et al.

International Application No.: PCT/US03/01981

International Filing Date: January 17, 2003

For: IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDE FOR
PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH
PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE
PATHWAYS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT / TRANSMITTAL ACCOMPANYING CD-ROM SUBMISSION OF
SEQUENCE LISTING**

Dear Sir:

Transmitted herewith is a Sequence Listing in the form of 3 (three) copies of a compact disc (CD-ROM) in accordance with 37 C.F.R. §1.52(e)(2)-(6). The three copies of the CD-ROM are intended to serve as:

- (1) a compact disc (CD-ROM) containing the Sequence Listing for the above-identified patent application as required by 37 C.F.R. §1.821(c) ("Copy 1"). The compact disc contains the Sequence Listing material created on July 7, 2004, of 2.00 megabytes in size, in PC/MS DOS PatentIn 3.2 format;
- (2) a duplicate copy of the compact disc (CD-ROM) as required by 37 C.F.R. §1.52(e)(4), ("Copy 2"). The compact disc contains the Sequence Listing

material created on July 7, 2004, of 2.00 megabytes in size, in PC/MS
DOS PatentIn 3.2 format; and

- (3) a compact disc (CD-ROM) copy in computer-readable form as required by
37 C.F.R. §1.821(e). The CD-ROM contains a CRF copy of the
Sequence Listing material created on July 7, 2004, of 2.00 megabytes in
size, in PC/MS DOS PatentIn 3.2 format.

Further, as required by 37 C.F.R. §1.821(f), it is hereby stated that the contents
of the Sequence Listing on all three of the CD-ROMs, as submitted herewith, are the
same.

Respectfully submitted,

BRISTOL-MYERS SQUIBB COMPANY

Date: 7/9/04

By: 
Stephen C. D'Amico
Registration No. 46,652

Correspondence Address:
BRISTOL-MYERS SQUIBB COMPANY
P.O. Box 4000
Route 206 and Provinceline Road
Princeton, NJ 08543
Telephone: (609) 252-5289
Facsimile: (609) 252-4526